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Abstract 
Tularemia is a zoonotic disease caused by the facultative intracellular bacterium 
Francisella tularensis. Recurrent outbreaks with hundreds of cases are reported in Finland 
and Sweden every few years. In other European countries the disease is quite rare, but 
sporadic outbreaks have been reported from various countries.  
 
Specific risk factors associated with ulceroglandular and pneumonic tularemia were 
investigated in a population-based case-control study presented in this thesis (study I). In 
addition, the public health impact of tularemia in Finland was analyzed and information on 
clinical features of the disease and patient characteristics was collected. Reported 
mosquito bites and farming activities were independently associated with ulceroglandular 
tularemia, whereas exposure to hay dust was associated with pneumonic tularemia. 
 
Spatial and temporal epidemiology of tularemia in Finland was investigated based on 
notifications to the National Infectious Disease Register (study IV). The prevalence of F. 
tularensis –antibodies in the adult general population was studied using serum samples 
from a nationwide population-based health survey (study IV). A serologic response to F. 
tularensis was found in 2% of the population.  
 
Occurrence of F. tularensis in wild rodents was studied by screening a total of 547 wild 
small mammals from 14 locations around Finland for the presence of F. tularensis DNA 
by PCR analysis (study II). High copy numbers of F. tularensis-specific DNA were 
detected in tissue samples of only 5 field voles originating from one location.  
 
The pathogenesis of F. tularensis infection in wild voles was studied in an experimental 
infection (study III). A rapid lethal clinical course, bacteremia and tissue necrosis were 
observed in the infected field voles and bank voles. The correlation between vole 
 
 
 
 
7 
population cycles and human tularemia outbreaks was assessed using surveillance data 
from 1995-2013 (study IV). Vole population peaks clearly preceded subsequent tularemia 
outbreaks one year later.  
 
In conclusion, this thesis describes risk factors for tularemia as well as the clinical 
characteristics and epidemiology of the disease in Finland. Moreover, the kinetics of F. 
tularensis infection in voles and the occurrence of F. tularensis in wildlife in Finland are 
represented. Since 1995, more than 5000 cases of tularemia have been reported. About 2% 
of the adult population has antibodies against F. tularensis. Incidence and seroprevalence 
are highest in Northern Ostrobothnia. Ulceroglandular and pneumonic tularemia have 
different risk factors. In rodents, F. tularensis infection is rare and mostly fatal. Rodents 
act as amplification hosts of F. tularensis, and high rodent densities predict tularemia 
outbreaks in humans in the following year. 
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1 Introduction 
The Centers for Disease Control and Prevention (CDC) consider the bacterium 
Francisella tularensis to be a Category A select agent with potential for use as a biological 
weapon (http://www.cdc.gov/Tularemia/).  This classification is due to the very high 
infectivity combined with relative stability of F tularensis in aerosols and the high 
morbidity from respiratory tularemia. In addition to F. tularensis, only two bacteria belong 
to this category, namely Yersinia pestis and Bacillus anthracis, the causative agents on 
plague and anthrax. Both the former Soviet Union and the USA have had programs to 
develop weapons that would disseminate F. tularensis aerosols.  
Tularemia, the zoonotic disease caused by F. tularensis, occurs naturally in many regions 
of the northern hemisphere. F. tularensis can be transmitted to humans directly from 
infected wildlife or more frequently through the bite of an arthropod vector. The disease is 
caused by two different subspecies: F. tularensis subsp. tularensis (type A), which is 
almost completely restricted to North America, and F. tularensis subsp. holarctica (type 
B), which is spread throughout the entire Holarctic region, including Finland. Type B is 
less virulent and usually nonlethal in humans, but it may still cause severe long-lasting 
disease. Tularemia often presents with non-specific symptoms, which may delay its 
diagnosis, especially in non-endemic areas. Finland repeatedly reports among the highest 
number of tularemia cases worldwide. The ecology of tularemia is complex and 
knowledge of its epidemiology is incomplete. The factors prompting tularemia outbreaks 
are still for the most part unclear. The main purpose of this thesis study was to describe 
the epidemiology of tularemia in Finland and to elucidate the risk factors for tularemia. 
The role of rodents in the ecology of tularemia and their susceptibility and response to F. 
tularensis were other targets of the study. Before this study, the occurrence of F. 
tularensis in Finnish wildlife as well as the prevalence of F. tularensis -antibodies in the 
population were unknown. 
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2 Review of the literature 
2.1. Francisella tularensis 
Francisella tularensis is a small (0.2–0.7μm), aerobic, Gram-negative (faintly staining), 
nonmotile, non-spore-forming coccobacillus belonging to the γ-subclass of Proteobacteria 
(Dennis et al. 2001, Keim et al. 2007, Sjösted 2007, Oyston 2008). Its outer membrane has 
an unusually high level of fatty acids with a unique profile and a structurally and 
antigenically unique lipopolysaccharide (LPS) that does not have general toxic or 
immunogenic properties (Okan et al. 2013, Jones et al. 2014). Virulent strains of F. 
tularensis have a thin capsule, which makes them resistant to the killing activity of serum 
complement (Clay et al. 2008, Jones et al. 2014). The size of the F. tularensis genome is 
about 1.9 Mb (Larsson et al. 2005) and it contains a pathogenicity island (FPI, required for 
phagosomal escape) that includes 19 genes essential for virulence (Nano et al. 2004). The 
taxonomic position of F. tularensis has repeatedly been changed. Originally, it was 
classified in the genus Bacterium, later in the genus Pasteurella, and it was subsequently 
placed in the genus Brucella (Ellis et al. 2002, Oyston et al. 2004). Finally, in 1947, it was 
assigned to the new genus Francisella. Based on modern 16SrRNA sequence 
comparisons, the most closely related but still distant human pathogens are Coxiella 
burnetii and Legionella pneumophila (Larsson et al. 2005) (Figure 1). Francisella 
tularensis was first discovered in Tulare County, California, USA, in 1911 from ground 
squirrels found dying of a plague-like illness (Oyston 2008).  
 
Four subspecies of Francisella tularensis with different geographical distributions and 
virulence have been identified. The disease tularemia is caused by two of the subspecies: 
F. tularensis subsp. tularensis (type A), which occurs mainly in North America, and 
subsp. holarctica (type B), which is endemic in many countries of the Northern 
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Hemisphere, including Finland (Ellis et al. 2002, Johansson et al. 2004, Sjöstedt 2007). 
Francisella tularensis subsp. mediasiatica is rare and has been found only in Central Asia; 
F. tularensis subsp. novicida occurs in North America and Australia (Oyston et al. 2004, 
Matayas et al. 2007). Other species in the genus Francisella (Figure 2) are mainly water-
related and have not been associated with tularemia-like illness. In addition to water-
related species, Francisella –like bacteria have also been found to reside in ticks. These 
Francisella-like-endosymbionts are nonpathogenic and probably not even transmitted to 
mammals by tick bite (Keim et al 2007). The subspecies holarctica (former palaearctica) 
is further separated into three biovars: biovar I (erythromycin sensitive), biovar II 
(erythromycin resistant), and Japonica (Kudelina et al. 1980, Ellis et al. 2002). The 
subspecies tularensis has been divided into three distinct genotypes: A1a, A1b, and A2 
(Kiersten et al. 2009). The subtype A1b is considered the most virulent. 
  
Francisella tularensis is a facultative intracellular pathogen that infects multiple cell 
types, including phagocytes as well as epithelial and endothelial cells, but its primary 
target cell is the macrophage (Sjöstedt 2007, Oyston 2008). It enters macrophages with a 
unique system of pseudopod loops (Clemens et al. 2005), replicates in the cytoplasm, and 
is released by the induction of apoptosis (Oyston 2008). Unlike other Gram-negative 
bacteria, the LPS of F. tularensis does not act as a typical endotoxin, nor does F. 
tularensis produce any other toxins (Ellis et al. 2002, Oyston et al. 2004). The LPS of F. 
tularensis does not bind to host molecules such as LPS-binding protein and TLR4 to 
trigger a proinflammatory response (Barker et al. 2006). Instead, F. tularensis is even 
capable of downregulating proinflammatory cytokines (Telepnev et al. 2003). The 
virulence of F. tularensis is mostly based on its ability to evade host immune responses 
and to enter, persist, and replicate within macrophages (Steiner et al. 2014). When grown 
in cysteine-supplemented medium, F. tularensis produces hydrogen sulfide. It is oxidase 
negative and weakly catalase positive (Sjöstedt 2005). The subspecies tularensis ferments 
glycerol and maltose, but not sucrose, whereas the subspecies holarctica ferments maltose 
but not sucrose or glycerol (Foley et al. 2010). Repeated transfers on media may reduce 
virulence. 
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Figure 1. Phylogenetic relationship of 16 -proteobacterial species inferred from a 
concatenated alignment of the proteins encoded by dnaA, ftsA, mfd, mraY, murB, murC, 
parC, recA, recG, and rpoC. Bacillus anthracis was used as the outgroup. The topology, 
branch lengths, and bootstrap support are according to the reconstruction with the 
neighbor-joining method. Values at nodes are bootstrap support values for the neighbor-
joining and maximum parsimony methods (in that order). Reprinted from Larsson et al. 
2005 with permission. 
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Figure 2. Phylogeny of Francisella and representative relatives based upon 1070 bp of the 
16S RNA gene sequences. The scale bar indicates the genetic distance of 0.02 nucleotide 
changes per site. Reprinted from Keim et al. 2007 with permission. 
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2.2. Ecology and epidemiology of tularemia 
2.2.1. Life cycle of F. tularensis in nature 
Tularemia is a zoonotic infection that naturally occurs in the northern hemisphere. 
Francisella tularensis is widespread and has an extensive host range; it can infect several 
wildlife species, domestic animals, and humans (Dennis et al. 2001). Outbreaks, however, 
are rare in most areas. Francisella tularensis does not produce spores, but it can survive in 
water, soil, straw, and animal carcasses for several months (Pomanskala 1956, Gilbert et 
al. 2012). Survival is longest under winter conditions (Pomanskala 1956). It has been 
shown that F. tularensis multiplies in amoebae at the same level as in macrophages (Abd 
et al. 2003). Since amoebae are commonly found in water and soil as a part of their normal 
biofilms, and the infection process in amoebae resembles that in macrophages, it can be 
assumed that amoebae serve as environmental hosts for F. tularensis (Abd et al. 2003, 
Broman et al. 2011). Furthermore, mosquito larvae feed on aquatic protozoa and hence 
can become infected with F. tularensis in their natural aquatic environment (Lundström et 
al. 2011). As adults, mosquitos then transmit the bacterium to susceptible hosts (Thelaus 
et al. 2013, Bäckman et al. 2015).  
 
The time-dependent evolution of F. tularensis is low. This bacterium persists in the 
environment in highly localized subpopulations in an inactive stage over years (Svensson 
et al. 2009, Johansson et al. 2014). The genetic diversity within the subspecies holarctica 
however, is broad, and multiple genetic clades are found in isolates obtained during 
natural tularemia outbreaks indicating environmental point sources of tularemia (Svensson 
et al. 2009, Karlsson et al. 2013, Johansson et al. 2014, Sissonen et al. 2015). The 
distribution of tularaemia caused by F. tularensis subsp. holarctica has been associated 
with closeness to water (and hence mosquito breeding sites), and recently, a positive 
correlation between the incidence of tularemia and the proportion of a municipality area 
covered by inland water has been found in Sweden (Desvars et al. 2015). It is suggested 
that aquatic protozoa enable F. tularensis to persist in natural waters at the specific 
locations where outbreaks occur and outbreaks are prompted by ecological or other 
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environmental factors like weather conditions favorable for mosquitos (Ryden et al. 2012, 
Bäckman et al. 2015, Sissonen et al. 2015). 
  
2.2.2. Francisella tularensis in wildlife 
Among wildlife species, lagomorphs and rodents are generally the most susceptible to this 
disease (Mörner 1992). Clinical signs of tularemia in wildlife are not well documented; 
investigations have only been conducted on dead animals (Hestvik et al. 2015). 
Francisella tularensis infection in lagomorphs and rodents is probably usually acute and 
fatal (Mörner 1992, Mörner et al 1988). In post-mortem examination, multifocal necrosis 
in the liver, spleen, and bone marrow are typically found (Mörner et al. 1988, Wobeser et 
al. 2007, Nelson et al. 2014), but chronic lesions such as granulomas have also been found 
in infected hares (Gyuranecz et al. 2010). Since 2000, the Finnish Food Safety Authority 
(Evira) has screened 100–250 hares and brown hares, and a few other animal species 
yearly for tularemia. The proportion of tularemia-positive samples has been 0–25%, 
depending on the year. All the animals tested by Evira have been found dead in nature. 
 
Serological studies on wildlife populations in Europe have demonstrated that exposure to 
F. tularensis is relatively common. Antibodies against F. tularensis have especially been 
detected in wild carnivores (Kuehn et al. 2012) and beavers (Mörner et al. 1983), but not 
in other rodents or lagomorphs (Mörner et al. 1988, Kaysser et al. 2008, Gyuranecz et al. 
2010). This supports the hypothesis that these animal species are highly susceptible to 
tularemia. Foxes and raccoon dogs have been suggested to be proper biological indicator 
species for the presence of F. tularensis in the wild (Kuehn et al. 2012). 
 
2.2.3. Tularemia in domestic animals 
Only a few reports on tularemia in domestic animals can be found in the literature. 
Infection with F. tularensis is probably relatively common in endemic areas, but disease 
outbreaks in domestic animals are rare (Nordstoga et al. 2014). Most domestic animals are 
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considered relatively resistant to infection. Of the domestic species, cats, rabbits, and 
sheep are most susceptible to tularemia. Clinical manifestations of the disease in animals 
resemble those in humans (Foley et al. 2010, Nordstoga et al. 2014). Feline tularemia is 
most commonly reported. Apparently, cats acquire the disease by hunting infected rodents 
(Foley et al. 2010). The most common signs of tularemia in cats are anorexia, lethargy, 
fever, and mandibular lymphadenopathy (Woods et al. 1998, Foley et al. 2010, Carvalho 
et al. 2014). Tularemia should be considered a differential diagnosis of unexplained febrile 
illnesses in outdoor cats living in areas where the disease is endemic (Magnarelli et al. 
2007). Infection with subsp. tularensis can be lethal if untreated (Baldwin et al. 1991, 
Berman-Booty et al. 2010).  
 
In post-mortem examination, multifocal necrosis in the spleen, liver, and lymph nodes are 
the most typical findings (Baldwin et al. 1991, Berman-Booty et al. 2010). Dogs are 
considered less susceptible to tularemia, and signs of the disease in them are rarely 
reported (Foley et al. 2010, Carvalho et al. 2014). Only one report of canine tularemia has 
been published from Europe (Nordstoga et al 2014), and only sporadic cases from North 
America (Gustafson et al. 1996, Meinkoth et al. 2004). Tularemia should be considered a 
differential diagnosis in hunting dogs with signs of fever, lethargy, anorexia, and pain. 
Symptoms in dogs are unspecific and self-limiting, and infection is probably often 
overlooked (Nordstoga et al. 2014).  
 
2.2.4. Epidemiology of human tularemia 
The epidemiology of tularemia varies worldwide and the incidence from many countries is 
not known. There are differences in the epidemiology of tularemia between the US and 
Europe, but also between different European countries. Tularemia has been reported from 
many countries of the Northern Hemisphere (Figure 3a & 3b), most frequently Finland 
and Sweden where it occurs endemically (Tärnvik et al. 2004, Splettstoesser et al. 2009). 
Recent outbreaks have also been reported from Kosovo (1999–2000), Massachusetts, 
USA (2000), France (2004), Turkey (2004–2005), Germany (2005 and 2012), Spain 
(2007), and Norway (2011) (Table 1). Both German outbreaks occurred among 
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participants in a hare hunt (Hauri et al. 2010, Otto et al. 2015), whereas the outbreaks in 
Kosovo, Turkey, and Norway were linked to rodents and contaminated drinking water 
(Reintjes et al. 2002, Grunow et al. 2012, Wilke et al. 2009, Larssen et al. 2011). In 
Massachusetts and Spain, landscaping was identified as a risk factor for exposure 
(Feldman et al. 2001, Feldman et al. 2003, Allue et al. 2008). In Italy, most cases of 
tularemia occur in winter and spring, and contaminated water is thought to be the main 
source of infection (D'Alessandro et al. 2014). Contaminated drinking water was also 
found to be the source of infection in the Republic of Georgia in 2006 (Chitadze et al. 
2009), and a waterborne outbreak associated with crayfish fishing was reported from 
Spain in 1998 (Anda et al. 2001).  
 
Although F. tularensis has a broad geographical distribution (Figure 3) and a wide range 
of animal hosts, such as rabbits, hares, voles, and other rodents, tularemia outbreaks are 
rare and occur for unknown reasons locally in geographically restricted areas (Sjöstedt 
2007, Svensson et al. 2009). The life cycle of F. tularensis in nature is not entirely known. 
In addition to mammals, subspecies holarctica has also been isolated from surface water, 
mud, and mosquito larvae collected in endemic areas (Broman et al. 2011, Lundström et al 
2011), which supports the hypothesis that F. tularensis subspecies holarctica could persist 
in natural waters, possibly in aquatic amoebae. However, there is also evidence that 
rodents play an important role in the ecology of tularemia, since there appears to be a 
correlation between tularemia outbreaks and preceding peaks of vole cycles, at least in 
Finland, Sweden (Tärnvik et al. 1996), and Hungary (Gyuranecz et al. 2012). Furthermore, 
outbreak investigations suggest that high rodent population densities may initiate 
tularemia outbreaks in humans (Reintjes et al. 2002, Allue et al. 2007, Grunow et al. 
2012). Exposure to rodents or their droppings was suspected to be the source of infection 
in a large tularemia outbreak in Kosovo in 1999–2000 (Reintjes et al. 2002, Grunow et al. 
2012). Relatively high prevalences of F. tularensis infections in wild rodents have been 
detected at human tularemia outbreak sites in Germany (Kaysser et al. 2008), China 
(Zhang et al. 2006), Slovakia, and Austria (Gurycova et al. 2001). Between the epidemics, 
however, the pathogen is only rarely found in rodents (Vest et al. 1965, Arata et al. 1973, 
Broman et al. 2011, Gyuranecz et al. 2011). 
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The highly virulent subspecies tularensis is principally found in North America, where 
mice, rats, rabbits, hares, and squirrels may carry these bacteria and ticks are considered 
the most important vector transmitting tularemia among wild animal populations and from 
animals to humans (Matayas et al 2007, Sjöstedt 2007, Foley et al. 2010).  
 
 
 
 
Figure 3. Worldwide distribution map of the four main Francisella subspecies. Countries 
where tularemia has been reported are shown in red. Reprinted from Oyston et al. 2004 
with permission. 
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Table 1. Characteristics of tularemia outbreaks in European countries 2000–2014.
  
Country and 
outbreak year 
Number 
of cases 
Source of 
infection 
Most common 
clinical forms 
References 
Kosovo 
1999–2000 
3271 Food and water 
contaminated by 
F. tularensis-
infected rodents 
and their feces 
Oropharyngeal Reintjes et al. 
2002 
Sweden 
2000 
4642 Mosquito bites Ulceroglandular Eliasson et al. 
2002 
Finland 
2000 
9262 Mosquito bites 
and hay dust 
Ulceroglandular Rossow et al. 
2014 (study I) 
Turkey 
2004–5 
1351 Contaminated 
drinking water 
Oropharyngeal Wilke et al. 2009  
France 
2004 
151 Aerosols from a 
dog’s fur 
disseminated by 
the dog shaking 
itself 
Pneumonic Siret et al. 2006 
Germany 
2005 
111 Infected hares 
shot at a hare 
hunt 
Typhoidal Hauri et al. 2010 
Finland 
2007 
4032 Mosquito bites Ulceroglandular Jounio et al. 2010 
Spain 
2007 
5071 Rodents Typhoidal Allue et al. 2008 
Sweden 
2010 
4842 Not reported Not reported Johansson et al. 
2014 
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Norway 
2011 
1802 Contaminated 
drinking water 
Oropharyngeal Larssen et al. 
2011 
Germany 
2012 
71 Infected hares 
shot at a hare 
hunt 
Typhoidal Otto et al. 2015 
1Number presented in the cited publication 
2Number of cases reported from the whole country in the epidemic year 
2.3. Clinical features of tularemia 
2.3.1. Clinical manifestations 
 
Tularemia is a challenging disease, not only for the patients, but also for clinicians, 
clinical microbiologists, and public health professionals. F. tularensis is widespread and 
highly infectious for humans, but the disease is beyond outbreaks in endemic areas 
uncommon, sources of exposure are various, and the clinical spectrum is broad (Weber et 
al. 2012). Often, the clinical symptoms are nonspecific. The clinical manifestations of F. 
tularensis infection in humans mainly depend on the route of infection and can be divided 
into two main groups: ulceroglandular and typhoidal (Oyston 2008) (Table 2). Humans 
can become infected through arthropod bites, direct contact with carcasses of infected 
animals, by inhalation of infective aerosols generated though agricultural, landscaping, or 
laboratory activities, or by ingestion of contaminated food or water (Dennis et al. 2001, 
Weber et al. 2012). One documented case of pneumonic tularemia with bacteremia 
occurred after the inhalation of contaminated brackish water in a near-drowning accident 
in France (Ughetto et al. 2015).  
 
The incubation period of tularemia is about 3–5 (range 1–21) days and the disease onset is 
acute with non-specific influenza-like general symptoms, especially fever, chills, and 
headache (Tärnvik et al. 2007). Two F. tularensis subsp. cause clinical infections in 
humans: F. tularensis subsp. tularensis (type A) and F. tularensis subsp. holarctica (type 
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B), which is more widespread (Johansson et al. 2004). Although disease forms are similar 
with both, subsp. tularensis generally causes a more fulminate and severe disease than 
subsp. holarctica (Tärnvik et al. 2003, Johansson et al. 2014). Infection with the most 
virulent strains can have a case fatality rate of 30% if untreated (Dennis et al. 2001). 
However, tularemia responds well to antibiotic treatment.  
 
Ulceroglandular and glandular tularemia 
Ulceroglandular tularemia, the most common form, is caused by vector-borne 
transmission or other percutaneous inoculation of F. tularensis (Tärnvik et al. 2003). At 
the onset, patients experience systemic flu-like symptoms, including fever, chills, 
headache, and myalgia (Dennis et al. 2001, Nigrovic et al. 2008). At the same time, a 
painful maculopapular lesion, which later ulcerates, develops at the inoculation site (Ellis 
et al. 2002, Tärnvik et al. 2003, Nigrovic et al. 2008). This is accompanied by substantial 
regional lymphadenopathy (Tärnvik et al. 2003, Hanke et al. 2008, Nigrovic et al. 2008). 
The lymphadenopathy is actually the usual cause for medical attention, whereas the 
primary ulcer can remain even unnoticed (Tärnvik et al. 2003). Cases without skin or 
mucosal ulceration are diagnosed as glandular tularemia (Tärnvik et al. 2007). In the 
oropharyngeal form, the primary ulcer is in the pharynx, and in the oculoglandular form in 
the eye (Tärnvik et al. 2007). In all of these syndromes, regional lymph nodes are 
extensively enlarged. Without treatment, lymph node suppuration frequently occurs 
(Tärnvik et al. 2003, Tärnvik et al. 2007). 
 
Pneumonic and typhoidal tularemia 
Pneumonic tularemia may occur directly after inhalational exposure to aerosolized F. 
tularensis (primary pneumonia) or secondarily as a complication of any other disease form 
through the hematogenous spread of F. tularensis (Tärnvik et al. 2003, Tärnvik et al. 
2007, Nigrovic et al. 2008). Primary pneumonia of type A tularemia presents the most 
serious form of F. tularensis infection, with a mortality rate of up to 60% if untreated 
(Dennis et al. 2001, Tärnvik et al. 2003). Pneumonic type A tularemia is a fulminant 
illness characterized by high fever, chills, dyspnea, chest pain, cough, and general 
weakness (Tärnvik et al. 2007, Nigrovic et al. 2008). Infection with F. tularensis subsp. 
holarctica through the respiratory route usually presents as an atypical pneumonia or the 
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typhoidal form, which is very difficult to diagnose due to nonspecific symptoms and 
numerous other potential causes with similar symptoms (Dahstarnd et al. 1971, Syrjälä et 
al. 1985, Tärnvik et al. 2003, Cunha 2006, Thomas et al. 2010, Weber et al. 2012).  
 
 
Table 2. Clinical forms of tularemia, the routes of infection and main symptoms. 
 
Disease form Route of infection Main symptoms 
   
Ulceroglandular/ glandular Arthropod bites, direct 
contact 
Cutaneous ulcer, lymph 
node enlargement, fever, 
myalgia 
Oculoglandular Direct inoculation on 
conjunctiva, dust 
Unilateral conjunctivitis, 
swelling of the eyelids and 
local lymph nodes 
Oropharyngeal Ingestion Pharyngitis, fever, swollen 
cervical lymph nodes 
Respiratory Inhalation Atypical pneumonia (fever, 
headache, myalgia, weight 
loss) 
Typhoidal Unknown, inhalation Severe systemic symptoms 
without specific organ 
manifestations 
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2.3.2. Pathogenesis and pathology 
Francisella tularensis, especially subsp. tularensis, is highly virulent and only 10–50 CFU 
are sufficient to cause disease in humans and other mammals. Infection can be transmitted 
through arthropod bites, direct contact with the carcasses of infected animals, by 
inhalation of infective aerosols, or by ingestion of contaminated food or water. After 
invasion, F. tularensis multiplies predominantly within macrophages. It is taken up by 
macrophages by inducing them to produce asymmetric pseudopod loops and then degrade 
the phagosomal membrane to escape to the cytoplasm (Clemens et al. 2005, Oyston 2008). 
In the cell, F. tularensis inhibits phagosome fusion and survives by suppression of 
acidification (Clemens et al. 2007, Sjöstedt 2007). After replication in the cytoplasm, it 
induces apoptosis to release large numbers of bacteria from the dying cell (Oyston 2008). 
Intracellularly, it disseminates first to the local lymph nodes and then via lymphatic 
vessels or hematogenously to multiple organs, particularly the liver, spleen, lung, and 
kidney (Thomas et al. 2010). The LPS of F. tularensis does not act as a typical endotoxin; 
it induces very little proinflammatory response compared to other Gram-negative bacteria 
(Sandström et al. 1992, Forestal et al. 2003, Barker et al. 2007, Steiner et al. 2014). 
Francisella tularensis is even capable of downregulating proinflammatory cytokines 
(Telepnev et al. 2003). Lesions caused by F. tularensis may resemble those seen in 
tuberculosis (Syrjälä et al. 1986), but due to faster bacterial replication, tularemia develops 
much more rapidly. In histopathological examination, tularemia typically presents with 
necrotizing granulomas found in the patient’s lymph nodes and other target organs 
(Navarro et al. 2011, Yildirim et al. 2014, Strehl et al. 2014).  
 
2.3.3. Laboratory diagnostics 
Laboratory diagnosis of F. tularensis infection is mainly based on serology. Serology can 
be used for all clinical forms of tularemia. Antibodies against F. tularensis reach a 
detectable level 1–2 weeks after the onset of symptoms (Koskela et al. 1985, Tärnvik et al. 
2007). Agglutination assays are the standard serological tests for tularemia diagnostics, 
but ELISA tests have also been developed for this purpose (Koskela et al. 1985, Schmitt et 
al. 2005, WHO 2007). The specificity of tularemia serology is high in both agglutination 
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assays and ELISA, and cross-reactions are rare (Tärnvik et al. 2007). The antibody levels 
reach their peak at 4–7 weeks after infection and stay detectable with declining titers for 
several years (Koskela et al. 1985). If suitable tissue specimens are available, culture or 
PCR can also be used for diagnostics. Culture and PCR-based methods are most useful in 
suspected ulceroglandular tularemia, when a wound specimen can be taken from the 
primary lesion (Johansson et al. 2000, Eliasson et al. 2005). PCR is more sensitive than 
culture for demonstration of F. tularensis in wound specimen (Johansson et al. 2000). 
Successful culture is also more dependent on selection of the right transport medium. 
 
Culture however is rarely used in routine clinical diagnostic of tularemia because F. 
tularensis is difficult and hazardous to grow in culture (Tärnvik et al. 2007, Nigrovic et al. 
2008). It is a relatively slow growing bacterium, requires a cysteine-enriched agar, and 
culture work must be done under BSL-3 conditions (Dennis et al. 2001, WHO 2007, 
Nigrovic et al. 2008). F. tularensis grows best at a temperature of 37 oC and a pH of 6.9 
(Foley et al. 2010). Colonies appearing after 24–48 hours of incubation are small, flat, pale 
gray, shiny, easily emulsified, and surrounded by alpha-hemolysis (Foley et al. 2010). 
They reach the maximum size in 3–4 days (Sjöstedt 2005). The identity of colonies can 
easily be tested by slide agglutination or by direct fluorescent antibody staining (Tärnvik 
et al. 2007). Isolation of F. tularensis from blood culture is very rare, and most cases have 
been reported from the USA (Haristoy et al. 2003, Karagöz et al. 2012). F. tularensis is 
one of the most infectious pathogens by the airborne route and therefore relatively 
commonly associated with laboratory-acquired infections.  
 
2.3.4. Treatment and prevention 
Antibiotic therapy should be started as soon as tularemia is suspected. A delay in proper 
treatment increases the risk of a severe disease course and complications, such as lymph 
node suppuration (Tärnvik et al. 2007, Weber et al. 2012). For the treatment of tularemia, 
streptomycin has been the golden standard for decades (Tärnvik et al. 2003). Other 
aminoglycosides such as gentamycin are also effective against tularemia, but these are all 
associated with toxicity and a parenteral administration route. Doxycycline is a safer 
alternative, but the risk of relapse is considerable if the treatment period is less than 14 
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days (Tärnvik et al. 2003, Tärnvik et al. 2007). At present, ciprofloxacin and other 
quinolones are recommended as the first choice in treating uncomplicated tularemia 
(Ikäheimo et al. 2000, Tärnvik et al. 2007). The development of antibiotic resistance is not 
a problem with F. tularensis, since Francisella is not a member of the commensal human 
flora and no person-to-person transmission occurs. However, there is widespread natural 
resistance to erythromycin among strains of subsp. holarctica (Ikäheimo et al. 2000).  
 
In case of accidental exposure (e.g. laboratory personnel), antibiotic treatment should be 
initiated within 24 hours (WHO 2007). It is also important to keep in mind that tularemia 
patients are not a source of infection for other people; direct human-to-human 
transmission of tularemia has never been reported. An attenuated live vaccine (LVS) was 
used for laboratory workers in the former USSR, US, and Japan, but it did not protect well 
against respiratory tularemia. Currently, no licensed vaccines against tularemia are 
available, but new vaccines are under development (Conlan 2011). Preventive measures 
against tularemia infection include protecting against mosquito bites, minimizing exposure 
to hay dust during landscaping activities and avoiding the handling of dead rodents and 
hares.  
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3 Aims of the thesis study 
 
1) To determine and evaluate the risk factors of different clinical forms of human 
tularemia during an outbreak and to assess the public health impact of tularemia in Finland  
 
2) To obtain information about the prevalence of F. tularensis -carriage in wild rodents in 
Finland  
 
3) To study the pathogenesis of F. tularensis subsp. holarctica –infection in an 
experimental trial, and thereby evaluate the potential of field voles (Microtus agrestis) and 
bank voles (Myodes glareolus) to spread the bacterium 
 
4) To describe the spatial and temporal epidemiology of human tularemia in Finland, to 
determine the prevalence of F. tularensis antibodies in the adult population, and to assess 
the role of vole population cycles in the temporal and spatial pattern of human tularaemia 
outbreaks 
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4 Materials and methods 
Detailed descriptions of materials and methods are given in the original publications I–IV. 
Some methods not described in the original articles are explained here more thoroughly. 
For others, the reference to the original publication is given in Roman numerals.  
4.1. Ethics (III & IV) 
Experimental procedures and facilities were approved by the Finnish Animal Experiment 
Board (Permit ESAVI/6162/04.10.03/2012), which followed the Finnish legislation for 
animal experiments. The Health 2000 Survey was approved by the Ethical Committee for 
Research in Epidemiology and Public Health at the Hospital District of Helsinki and 
Uusimaa. 
 
4.2. Cases and controls in the case-control study (I) 
Case patients for the case-control study were directly identified through active 
surveillance of diagnostic laboratories, and control subjects matched for birth, sex and 
postal code were listed from the National Population Information System. A case patient 
was defined as a person with laboratory-confirmed tularemia within the study period and 
who lived in one of the three endemic health districts (Fig. 1 in I). Patients with 
laboratory-confirmed tularemia and physician-diagnosed pneumonia were classified as 
pneumonia cases. Patients with laboratory-confirmed tularemia who reported enlarged 
lymph nodes and/or skin ulcers were classified as ulceroglandular cases (I). 
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4.3. Animals 
4.3.1. Collection of wild animals (II & III) 
Small mammals were trapped from 14 locations around Finland during six years by  the 
Natural Resources Institute, Finland. The trapped small mammals were predominantly 
rodents, mainly bank voles and field voles (II).  
 
4.3.2. Animals for experimental infections (III) 
Laboratory-borne adult visibly healthy field and bank voles were obtained from the 
Natural Resources Institute, Finland and kept in individually ventilated and HEPA-filtered 
isolation cages during the experimental infections (III). 
 
4.4. Bacterial strain used in experimental infections (III) 
The F. tularensis strain used to experimentally induce tularemia in voles had originally 
been isolated from a cutaneous ulcer of a 49-year-old woman and identified as subsp. 
holarctica by 16S rRNA gene sequencing. The strain was cultured and grown on 
chocolate agar plates at +35 °C in 5% CO2 for five days. MacFarland 1.0 suspension was 
prepared in sterile isotonic saline and diluted in a ten-fold series to an estimated 
concentration of 1000 cfu/ml. The definite concentration in each experiment was 
determined by plate counting. The diluted suspension was kept on ice and used for 
inoculations within 1–2 h of preparation. The viable count of F. tularensis in the 
remaining dilution was comparable to that of the fresh dilution. 
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4.5. Human serum samples (IV) 
Serum samples from a multidisciplinary epidemiologic health survey were obtained from 
the National Institute for Health and Welfare (THL) and stored at -70 °C. Sera from seven 
patients who had laboratory-confirmed tularemia between 1 and 16 years ago were used as 
positive control sera. Control sera were obtained from the Department of Medical 
Microbiology and Immunology, University of Turku (IV). 
 
4.6. Database material (I & IV) 
In Finland, laboratory-confirmed tularemia is a notifiable disease by the diagnosing 
laboratory. Clinical microbiology laboratories report cases to the National Infectious 
Disease Register (NIDR), which is maintained by THL. The notifications include 
information on the date and type of specimen, date of birth, gender, place of treatment, 
and place of residence. Diagnostic criteria for reporting include 1) the isolation of F. 
tularensis in a clinical specimen, 2) a >4-fold rise in the serum antibody titer, or a single 
antibody titer of >160 when using an agglutination assay, or 3) the presence of specific 
IgM and IgG antibodies in the serum when an ELISA-based assay is used.  
 
4.7. DNA extraction and PCR analyses (II & III) 
DNA was extracted from tissue samples of the wild-caught and experimentally infected 
animals and from the excreta of the experimentally infected animals with commercial kits. 
For tissue samples, the Wizard Genomic DNA Purification Kit (Promega, Madison, USA), 
following the protocol for animal tissue, was used. The QIAamp DNA Stool kit (Qiagen, 
Hilden, Germany) was chosen for fecal samples and the QIAamp Viral RNA Mini kit 
(Qiagen, Hilden, Germany), using the protocol for purification of cellular, bacterial or 
viral DNA from urine, for urine samples.  
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The DNA samples were analyzed with a semi-quantitative real-time PCR assay (qPCR) 
targeting the 23kDa gene of F. tularensis. All PCRs were run in duplicate with an ABI 
7500 instrument (Applied Biosystems, Foster City, CA, USA). DNA from tissue samples 
was analyzed using 1:100 dilutions, and for urine and fecal samples, three 10-fold 
(undiluted, 1:10, 1:100) dilutions were examined.  
 
A part of the bacterial 23S ribosomal RNA gene from three initially F. tularensis PCR-
positive samples was amplified and sequenced with an automated ABI 3130XL DNA 
sequencer (ABI) using the BigDye chemistry (ABI) and the Sequencer 4.0 program (Gene 
Codes Corporation, Ann Arbor, MI USA) (II).  
 
4.8. Histology and immunohistochemical staining (III) 
Tissue sections were collected immediately after euthanasia, fixed in 10% buffered 
formalin, routinely paraffin wax embedded, cut into 3–5 μm sections, and subjected to 
staining with hematoxylin-eosin (HE) or used for immunohistology (IH). IH was 
performed using a mouse monoclonal antibody against F. tularensis LPS (clone T14; 
Meridian Life Sciences, Memphis, USA) and the horseradish peroxidase method 
(Envision; Dako, Glostrup, Denmark) with diaminobenzidine as the chromogen, after 
antigen retrieval with citrate buffer (pH 6.0) microwave pretreatment (III). 
 
4.9. Serologic testing (IV) 
4.9.1. Enzyme-linked immunosorbent assay 
All serum samples were screened for F. tularensis antibodies with an enzyme-linked 
immunosorbent assay (ELISA) as previously described by Koskela et al. (1985). Whole 
bacterium lysate prepared from F. tularensis live vaccine strain (LVS) was used as the 
antigen in the ELISA assay. Microtiter plates (Thermo Fisher Scientific, Vantaa, Finland) 
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were coated with F. tularensis lysate (10 μg/ml) in phosphate buffered saline (PBS) at 37 
°C overnight, and washed twice with washing solution (H2O, 0.05% Tween 20, Merck, 
Hohenbrunn, Germany). The wells were saturated with 1% normal sheep serum (Bio 
Karjalohja Oy, Karjalohja, Finland) in PBS at 37 °C for two hours, and washed twice with 
washing solution. Serum samples were diluted 1:100 in 1% normal sheep serum in PBS. 
The wells were incubated with the diluted samples at 37 °C for 90 minutes, and washed 
three times with the washing solution. The wells were incubated with rabbit anti-human 
IgG antibody (1:3000; Dako, Glostrup, Denmark) at 37 °C for two hours, and washed 
three times with the washing solution. After washings, p-nitrophenyl phosphate (1 mg/ml; 
Reagena, Toivala, Finland) was added for 30 min before the reaction was stopped with 1 
M NaOH, and absorbances (OD405) were measured with the BEP III system (Siemens 
Healthcare Diagnostics Products GmbH, Erlangen, Germany). Results are expressed as 
arbitrary enzyme-immunosorbent units (EIU) on the scale from 0 to 100 units.  
 
4.9.2. Western blotting 
Western blotting was conducted as earlier described by Schmitt et al. (2005).  A formalin-
inactivated LVS suspension in LSB (125mM TRIS pH 6.8, 4% SDS, 20% Glycerol, 10% 
2-ME, 0.02% Bromophenol Blue) was boiled for 15 minutes, centrifuged with an 
Eppendorf tabletop centrifuge 20 minutes at 10 000 rpm, and electrophoresed at 130 V for 
about 1.5 hours using a 4–20% separating gel (Mini-Protean TGX 4–20%, BIO-RAD, 
Berkeley, California, USA). Bacterial antigens were transferred onto a nitrocellulose 
membrane at 200 mA for approximately one hour. Unspecific binding sites on the 
membrane were blocked with 4% skimmed milk in PBS overnight at 4 °C. The dried and 
cut membrane strips were incubated with sera diluted 1:100 in 4% skimmed milk in PBS 
for one hour. After washing the membranes three times with washing solution (TEN 
+0.05% Tween20), the strips were incubated with a monovalent goat anti-human IgG 
peroxidase conjugated immunoglobulin (Li-cor, Odyssey) diluted 1:10 000 in blocking 
buffer at room temperature for one hour. Following another three rinses with washing 
solution, the membranes were scanned with an Odyssey imaging system. Positive sera 
showed a typical LPS band pattern at a dilution of 1:100. Samples were screened from the 
highest EIU (83.7) in ELISA down to EIU 26.8 (including 55 serosurvey samples + 7 
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positive control samples). The last positive sample in WB had an ELISA EIU value of 
28.5. The following 10 samples were WB negative and screening was stopped due to the 
low EIU values of the remaining samples.  
 
4.10. Statistical analyses and study questionnaires (I & IV) 
In study I, conditional logistic regression was used to calculate matched odds ratios 
(mORs) and their 95% confidence intervals (CIs) for three main outcomes: 1) all tularemia 
cases, 2) ulceroglandular cases and 3) pneumonia cases. A P-value of ≤ 0.2 was used as 
the screening criterion for the selection of variables for multivariate analyses. Due to the 
survey design, the variables had varying proportions of missing responses. In Model 1, 
missing data were assumed to be missing at random and only subjects with complete 
information on variables in the final model are included. Model 2 was a Bayesian full 
likelihood analysis in which missing data were taken into account and became a 
multidimensional additional parameter. To include a variable in the final model, the 
required posterior probability was >50% in Gibbs’ variable selection. The Kolmogorov-
Smirnov test was used to compare distributions and the chi-squared test to assess the 
associations between variables among case patients (independent observations). Adjusted 
population-attributable risks (PARs) and their 95% confidence intervals for each 
independent risk factor were calculated on the basis of mORs from Model 2. Analyses 
were performed using Stata version 9.2 (Stata Corporation, USA) and Winbugs 1.4.3 
(MRC-bsu.Cambridge and Imperial College) (I). 
 
In study IV, statistical analyses were performed using IBM SPSS Statistics version 22. 
The original study questionnaire from the Health 2000 survey is available at: 
http://www.terveys2000.fi/data.html. Univariate chi-squared tests were used to test the 
independence of the categorical variables. Logistic regression was used to model the 
relationship between seroprevalence rates and explanatory variables. The notified/total 
tularemia incidence ratio was calculated by assuming a stationary population at risk and 
prevalence pool. Then, the prevalence odds of tularemia, p/(1-p) = I*D, where I is the 
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“total” incidence (notified + unnotified) and the D is mean residual life time of the mean 
age of acquiring tularemia. 
 
Poisson regression was used to analyze the association between tularemia outbreaks and 
the phase of the vole cycle. Calculations were performed according to the hospital district. 
The effect of vole cyclic phase factor was assumed to be year independent. Possible 
overdispersion was corrected by the Pearson chi-squared scale parameter method and 
possible autocorrelations of Pearson residuals from the model were checked by 
autocorrelation plots (IV).  
 
4.11. Study design in experimental infections (III) 
The experimental infections were conducted at the biosafety level 3 laboratory of the 
Faculty of Veterinary Medicine, University of Helsinki, Finland. In the pilot study, field 
voles were infected with four dose/route combinations: either 120 or 1200 cfu of F. 
tularensis subsp. holarctica, and either an intranasal or a subcutaneous delivery route. The 
animals were checked twice a day and euthanized immediately if they exhibited signs of 
illness. A full post-mortem examination was performed and tissue specimens collected for 
histological and PCR analyses. In the main experiment, 12 field voles and 12 bank voles 
were injected subcutaneously with a suspension containing 70 cfu of F. tularensis subsp. 
holarctica. Three animals of each species served as non-infected controls. Three infected 
voles of each species were euthanized on days one and three post-infection. The remaining 
voles were euthanized if symptomatic. At necropsies, samples of urine, feces, spleen, and 
kidney were aseptically collected and frozen at -80 °C for PCR analysis. Tissue specimens 
from lungs, liver, spleen, bone marrow, kidneys, stomach, duodenum, jejunum, colon, and 
the inoculation site were fixed in 10% buffered formalin for histological and 
immunohistological assessment (III). 
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5 Results and discussion 
5.1. Epidemiology of tularemia in Finland 
5.1.1. Descriptive epidemiology  
 
Up to 1995, over 5000 notifications of laboratory-confirmed tularemia cases have been 
reported to the NIDR in Finland. The annual number of notified cases has ranged from 14 
to 926; epidemics have typically occurred in different districts every 2–4 years (Table 3). 
The average annual incidence on the basis of these notified cases was 5.1/100 000 
population. During the largest epidemic on record in 2000, the tularemia incidence in 
Finland reached 18/100 000 population. Incidence rates and case numbers were typically 
highest in the healthcare districts of Northern and Southern Ostrobothnia and Central 
Finland (Figures 4 & 5). The mean age of patients was 45 years (range 0–93 years) 
(Figure 6), and 55% of the cases were males. Notifications were strongly seasonal, with 
the majority of cases diagnosed during the summer and early autumn. The cumulative 
number of cases per month for 1995–2014 showed a peak in August-September (Figure 
7). Almost 80% of the cases were notified during August or September. In epidemic years, 
3–5 localized outbreaks occurred concomitantly at different sites. The municipalities with 
the highest cumulative case numbers were Oulu, Haukipudas, Pori, Seinäjoki, and 
Kiiminki. The diagnosis of tularemia was confirmed in about 96% of the cases by 
serology, in more than 3% of the cases by culture, and in the remaining cases by PCR. 
 
Most European countries report only sporadic cases of tularemia, and larger epidemics 
rarely occur. Major outbreaks with several hundreds of cases regularly occur in Finland 
and Sweden, and less frequently in Russia. In France, Germany, Italy, and Poland, for 
example, the average tularemia incidence is about 100 times lower than in Finland or 
Sweden (Splettstoesser et al. 2009). Approximately 60–80% of all tularemia cases in 
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Europe are reported from Finland and Sweden. Other countries with notable case numbers 
are Norway, Russia, the Czech Republic, Hungary, and Slovakia (Tärnvik et al. 2004, 
Splettstoesser et al. 2009). In all countries, tularemia outbreaks are typically localized and 
most of the cases occur within small areas. This type of spatial pattern indicates 
environmental point sources of infection. The local ecological factors crucial for the 
persistence of F. tularensis in the environment, however, are still not very well known. 
The age and sex distribution and seasonality of tularemia in Finland, as well as the disease 
outcomes, are compatible with epidemiological data from Sweden (Desvars et al. 2015). 
Little long-term epidemiological information is available from other countries, but based 
on outbreak investigations, tularemia in Germany and France is mainly associated with 
hare hunting (Siret et al. 2006, Hauri et al. 2010, Maurin et al. 2011, Otto et al. 2015). 
Outbreaks in Norway, Turkey, and Kosovo have been linked to drinking water 
contaminated by rodents (Reintjes et al. 2002, Wilke et al. 2009, Larssen et al. 2011). 
Mosquito-borne transmission dominates in both Finland and Sweden (I, Eliasson et al. 
2002). 
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Figure 4. Total number of laboratory-confirmed cases of Francisella tularensis infections 
according to the healthcare district reported to the National Infectious Disease Registry 1995–
2013. 
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Figure 6. Cumulative number of notified tularemia cases according to age group, Finland 
1995–2014. 
 
 
 
Figure 7. Cumulative number of tularemia cases according to month of notification, Finland, 
1995–2014. 
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5.1.2. Risk factors for tularemia and F. tularensis seropositivity 
A population-based case-control study was conducted during the largest epidemic on record in 
2000. Factors associated with the different clinical forms of tularemia had not been previously 
evaluated in controlled studies. The typical symptoms (Table 1 in I) of case patients with 
ulceroglandular tularemia included fever (92%), lymphadenopathy (90%), cutaneous ulcer (82%), 
and myalgia (78%). Case patients with pneumonic tularemia most frequently reported fever (100%), 
weight loss (67%), myalgia (61%), and cough (60%). Pneumonia patents also frequently reported 
other symptoms such as headache and exhaustion. 
  
In general, mosquito bites, farming activities, and handling dead animals were associated with an 
increased tularemia risk. Risk factors for the different disease forms and patient characteristics, 
however, were various. In case patients with ulceroglandular disease, both genders were represented 
equally and age ranged from 4 months to 84 years (mean 42 years), whereas all pneumonia case 
patients were adults (their age ranged from 22 to 71 years, mean 52 years), and 70% of them were 
males (Table 1 & Figure 1 in I). 
 
Of the case patients with ulceroglandular tularemia, 98% reported arthropod bites within the two 
weeks before illness compared with 70% of controls. Of the specific arthropods, however, only 
mosquito bites and horse fly bites were significantly associated with disease. Of the case patients, 
93% reported mosquito bites compared with 69% of the controls; horse fly bites were reported by 
14% of cases and 5% of controls. In univariate analysis, other factors associated with 
ulceroglandular tularemia were outdoor activities, forestry work, farming activities, and handling 
dead animals (Table 2 in I).  
 
Mosquito-borne transmission has been considered the major transmission route of F. tularensis 
subsp. holarctica in Finland and Sweden (I, Lundström et al. 2011, Rydén et al. 2012, Thelaus et al. 
2013, Bäckman et al. 2015), and some of the largest epidemics have reported a link to mosquito 
bites (I, Eliasson et al. 2002). Mosquitos may already acquire the bacterium as larvae from their 
aquatic habitat (Lundström et al. 2011, Rydén et al. 2012, Thelaus et al. 2013, Bäckman et al. 
2015), and the persistence of the bacterium in natural waters of endemic areas, possibly in 
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association with amoebae, could explain the uneven geographical distribution of tularemia (Abd et 
al. 2003, Broman et al. 2011, Thelaus et al. 2013, Bäckman et al. 2015). The study participants were 
asked about being bitten by the different arthropods present in Finland. Mosquito and horse fly bites 
were associated with tularemia infection in univariate analysis, but after adjustment for other 
variables in multivariate analysis, only mosquito bites remained statistically significant. On the 
other hand, few subjects were exposed to arthropods other than mosquitoes, reducing the statistical 
power to calculate these associations. Study participants may also have had difficulties in 
identifying the various arthropod species or even noticing being bitten by an arthropod, possibly 
resulting in misclassification of exposure.  
 
Exposure to hay dust was the only exposure significantly associated with pneumonic tularemia 
(Table 3 in I). In the 2 weeks prior to illness onset, 55% of the pneumonia patients were exposed to 
hay, compared with 15% of controls. Some farming activities, such as harvesting hay, have the 
potential of aerosolizing environmental pathogens, and several airborne tularemia outbreaks have 
been linked to farm work (Dahlstarnd et al. 1971, Syrjälä et al. 1985, Allue et al. 2008). However, 
this was the first study quantifying the association in a controlled design. Most patients with 
pneumonic tularemia were men, supporting the link with a farming occupation. Some small 
outbreaks of airborne tularemia have been associated with other outdoor activities such as lawn 
moving (McCarthy et al. 1990, Feldman et al. 2001) or hunting (Siret et al. 2006, Hauri et al. 2010). 
In conclusion, respiratory tularemia has to be considered an occupational hazard for farmers in 
endemic areas. Due to the nonspecific nature of symptoms and clinical findings, the diagnosis of 
respiratory tularemia remains challenging (Rossow et al. 2011). 
 
In the serosurvey study, 1045 sera from randomly selected persons, representative for the Finnish 
population in each region, were screened with an enzyme-linked immunosorbent assay (ELISA) for 
the presence of IgG antibodies against F. tularensis, and positive results were further confirmed by 
immunoblotting. A serologic response to F. tularensis was found in 2% (95% confidence interval: 
1.1–3.5%) of the population (IV). No significant difference in the age or sex ratio was found 
between seropositive and seronegative groups. The mean age of seropositive persons was 55 years 
and 50% were males. No association was found between tularemia antibodies and long-term health 
problems. No single background factor was significantly associated with seropositivity. 
Geographically, the seroprevalence was highest in Northern Ostrobothnia (Figure 5 in IV). Based 
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on the number of notifications to the NIDR and the seroprevalence we found in our study, 
approximately 9.5% of all F. tularensis infections are notified. 
 
5.2. Francisella tularensis infection in rodents 
5.2.1. Pathogenesis and pathologic features 
Host responses and the pathologic features of experimentally induced F. tularensis infection in 
rodents have previously been described in a small number of studies (Conlan et al. 2003, Conlan et 
al. 2008, Bandouchova et al. 2009). In all studies, the course of disease has been fatal regardless of 
the dose or route. Previous studies, however, have mainly been conducted on laboratory mice and 
may not apply to wild rodents. Tularemia outbreaks in humans have been linked to high rodent 
densities (Allue et al. 2008, Reintjes et al. 2002, Grunow et al. 2012, Wilke et al. 2009, Larssen et 
al. 2011), and exposure to rodents or their droppings was suspected as the infection source in a large 
outbreak in Kosovo. Even chronic shedding of F. tularensis has been suggested when rodents are 
infected orally (Bell et al. 1975). Nevertheless, the exact role of rodents in bacterial maintenance, 
and the nature of their association with human disease have remained unclear.  
 
As a part of this thesis, the susceptibility and response of field voles (Microtus agrestis) and bank 
voles (Myodes glareolus) to F. tularensis subsp. holarctica was studied in an experimental trial 
(III). In a pilot study, voles were infected intranasally and subcutaneously with F. tularensis subsp. 
holarctica. Infected animals showed symptoms of severe acute illness on day 5 post-infection; 
approximately 65% of the animals were found dead and the remaining ones had to be euthanized 
due to endpoint symptoms (e.g. lethargy, anorexia, hunching). The pathologic, histopathologic, and 
immunohistochemical examination revealed findings characteristic for septicemia in all cases. 
Gross pathologic lesions were generally lacking, apart from splenomegalia in some individuals. 
Analyses of the pathogenesis showed that bacteria are taken up locally by macrophages and 
neutrophils and then disseminate to several organs by lymphohematogenous spread. Consequently, 
they can be found both within monocytes and cell free in vessels of almost all organs, leading to 
necrosis of infected cells (III). Thus, extensive necrosis, particularly in the lymphatic tissues (i.e. 
spleen and lymph nodes), was the most significant finding in F. tularensis-infected voles (Figure 2 
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in III). Interestingly, this is not associated with an evident inflammatory response. Bacterial 
aggregates were found in several organs, including within the glomerular tufts of the kidneys and in 
the intestinal mucosa (Figure 4 in III), which indicates that F. tularensis is excreted in urine and 
feces.  
 
Study III presents an experimental model that mimics natural F. tularensis subsp. holarctica 
infection of wild voles, and demonstrates that both field voles and bank voles are highly susceptible 
to the bacterium. Infected animals died with bacteremia, following a rapid clinical course and 
generally with very high bacterial loads in organs. PCR analysis also proved that infected voles 
excrete F. tularensis in their urine and feces around the time of death (Figure 3 in III). However, it 
cannot be ruled out that some individuals might have survived infection if the voles were exposed to 
F. tularensis orally. In the surviving individuals, shedding of bacteria might have lasted longer, 
possibly leading to more widespread contamination of the environment. 
 
5.2.2. Occurrence of Francisella tularensis in wild-caught voles and other rodents 
The occurrence of F. tularensis in wildlife had not been previously studied in Finland, and data 
from only a few other European counties had been published (Gurycová et al. 2001, Kaysser et al. 
2008, Broman et al. 2011, Gyuranecz et al. 2011, Grunow et al. 2012). Most of the previous 
investigations were carried out during or shortly after an outbreak at the outbreak site, whereas as a 
part of this thesis the occurrence of F. tularensis in rodents was studied in random locations with 
respect to tularemia occurrence in humans (Figure 1 in II). The presence of F. tularensis among 
wild-caught small mammals was examined with PCR screening of 547 individuals (II). The 
majority of the trapped animals were field voles (N = 237) and bank voles (N = 182), but lemmings, 
water voles, and a few other species were also included (Table 1 in II). Large amounts of F. 
tularensis DNA were detected in liver samples of 5 field voles (II). All PCR-positive animals 
originated from Konnevesi, Central Finland. Four out of five infected animals were males. One 
infected field vole was collected in fall 2008, whereas the rest were from spring 2009. Partial 
sequencing of the 23S rRNA gene from three positive samples confirmed the subsp. as Francisella 
tularensis subsp. holarctica. Comparison of the F. tularensis load in four organs of the five F. 
tularensis-positive animals showed that F. tularensis can be detected in samples of liver, lung, and 
spleen tissue, but the kidney is not always positive (Table 2 in II).  
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5.2.3. Linking human tularemia outbreaks to wildlife and arthropod vectors 
Francisella tularensis persists in the local ecosystems in a dormant stage and causes epidemics only 
when the ecological and environmental conditions are suitable for bacterial replication and 
transmission (Sjöstedt 2007, Ryden et al. 2012, Johansson et al. 2014). In most countries of 
Northern Europe and Scandinavia, tularemia outbreaks occur in late summer and early autumn (I, 
IV, Eliasson et al. 2002, Johansson et al. 2014, Desvars et al. 2015). Only Norway reports high case 
numbers during the winter months (Larssen et al. 2011, Larssen et al. 2014). Tularemia is typically 
associated with outdoor activities, and farmers and hunters are at particular risk of infection (I, 
Dahlstarnd et al. 1971, Eliasson et al. 2002, Calanan et al. 2007, Martín et al. 2007, Allue et al. 
2008, Hauri et al. 2010, Mailles 2014). In Finland and Sweden, the disease is classically mosquito-
transmitted and most cases are reported during August and September, related to the occurrence of 
mosquitos (I, IV, Eliasson et al. 2002).  
 
Airborne outbreaks, mainly associated with potentially aerosol-generating activities such as 
farming, gardening or hunting, rarely occur and remain very local (Dahlstarnd et al. 1971, Feldman 
et al. 2001, Siret et al. 2006, Hauri et al. 2010, Otto et al. 2015). In Norway, water-borne outbreaks 
are most common (Berdal et al. 2000, Larssen et al. 2011, Larssen et al. 2014), and in Kosovo, 
outbreaks have been linked to rodent contamination (Reintjes et al. 2002, Grunow et al. 2012). 
Rodents and lagomorphs can act as local amplifiers for F. tularensis and after death contaminate the 
environment, including the breeding sites of mosquitos (III, Thelaus et al. 2013, Bäckman et al. 
2015). Aquatic protozoa most likely enable F. tularensis to persist in natural waters at the specific 
locations where outbreaks occur (Abd et al. 2003), but outside epidemics, F. tularensis replicates, 
based on the absence of time-dependent evolution, rarely (Johansson et al. 2014). Weather 
conditions favorable for mosquitos impact on the transmission to humans, and thus, the size of 
outbreaks (Ryden et al. 2012).  
 
Tularaemia caused by subspecies holarctica has been associated with proximity to natural water, 
and a positive correlation between the tularemia incidence and the proportion of a municipality area 
covered by inland water has been found in Sweden (Desvars et al. 2015). In Finland however, such 
a correlation does not occur. Quite the contrary, the cumulative tularemia incidence in the Finnish 
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Lakeland is below the average (Figure 4, IV), but a correlation between vole population dynamics 
and human tularemia outbreaks has been indicated (IV). Rodent hosts enable bacterial replication 
bursts during outbreaks (III, Figure 8). A high vole density may thus be one, but not the only 
precondition for tularemia outbreaks. Not all local environmental and ecological factors critical for 
disease outbreaks are yet known very well. The variation in the magnitude and especially the 
locality of human tularemia outbreaks clearly deserves further analyses. Although tularemia is, 
because of its complex ecology, a difficult disease to control, infection surveillance in wildlife 
could possibly help to predict and prevent human tularemia outbreaks (Carvalho et al. 2014, 
Hestvik et al. 2015). 
 
 
 
 
Figure 8. Life cycle of F. tularensis in Finland. 
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6 Concluding remarks 
Tularemia is endemic in Northern and Southern Ostrobothnia and Central Finland. Recurrent 
regional and seasonal outbreaks involving hundreds of cases occur in the endemic areas every 3–4 
years. In other regions, outbreaks of this size are quite rare. The F. tularensis -antibody prevalence 
is 2% on the population level. Incidence and seroprevalence are highest in Northern Ostrobothnia.  
 
Tularemia causes severe illness and places a burden on the healthcare system during epidemics. 
Although the majority of the tularemia disease burden is attributable to mosquito bites, risk factors 
for ulceroglandular and pneumonic forms of tularemia are different, enabling targeted prevention 
measures. The risk of tularemia infection can be reduced by protecting against mosquito bites, using 
disposable gloves if handling dead rodents and lagomorphs, and by minimizing exposure to hay 
dust potentially contaminated with bacteria by wearing masks for respiratory protection while 
performing farming and landscaping activities. Physicians in endemic areas should consider 
tularemia in patients with acute febrile illness.  
 
Francisella tularensis infection in voles is rather rare outside epidemics. Field and bank voles are 
highly susceptible to F. tularensis, with infection leading to bacteremia, tissue necrosis, and death. 
Although septicemic voles may pose a substantial risk to humans during tularemia outbreaks and 
serve as amplification hosts for F. tularensis, we did not find evidence supporting the role of voles 
as a true reservoir of F. tularensis between outbreaks. 
 
A correlation can be shown between vole population dynamics and human tularemia outbreaks. 
Human tularemia outbreaks typically occur a year after the vole population peak. The dynamics of 
the vole population thus may be a factor of epidemiological importance, although not the only 
prerequisite for tularemia outbreaks. 
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